3.77

8.72% -0.36

Pre-market: 3.79 0.02 +0.53%

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $3.77, with a volume of 724.90K. It is down -8.72% in the last 24 hours and up +8.02% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$4.13

Open:

$4.14

24h Volume:

724.90K

Relative Volume:

1.26

Market Cap:

$207.07M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-1.4173

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

-13.73%

1M Performance:

+8.02%

6M Performance:

-35.88%

1Y Performance:

-83.57%

1-Day Range:

$3.73

$4.17

1-Week Range:

$3.73

$4.39

52-Week Range:

$2.235

$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (662)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	3.77	207.07M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	443.54	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	511.92	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	313.13	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	540.76	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	257.51	28.51B	3.81B	-644.79M	-669.77M	-6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025

Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025

Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025

Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025

Jun 04, 2025